Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2023-09-21 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰 2023年第一次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as materials for the "2023 First Extraordinary General Meeting of Shareholders" of 百奥泰生物制药股份有限公司. It includes detailed meeting instructions, agenda, and proposals to be voted on at the shareholders meeting, such as an energy management agreement with a related party and revisions to the Independent Director Work System. The content is focused on the meeting process, voting, and governance matters rather than financial results or audit information. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual or Extraordinary General Meeting. The document length is substantial and contains detailed meeting materials, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the appropriate classification is AGM Information (AGM-R).
2023-09-21 Chinese
百奥泰生物制药股份有限公司 独立董事工作制度
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System'. It details the rules, responsibilities, nomination, appointment, and duties of independent directors within the company. The content focuses on governance structure, board composition, director qualifications, and procedural rules for independent directors. There is no financial data, earnings information, or report publication mentioned. The document is a governance-related internal policy or regulation document. Therefore, it fits best under Governance Information (CGR). The document length is 8832 characters, indicating it is a full policy document rather than a brief announcement or certification.
2023-09-15 Chinese
百奥泰 与关联方签署分布式屋顶光伏电站能源管理协议暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about a related-party transaction involving the signing of a distributed rooftop photovoltaic power station energy management agreement between the company 百奥泰生物制药股份有限公司 and its related party 广州七喜电脑有限公司. It includes extensive information about the transaction terms, pricing, rights and obligations, necessity and impact on the company, and the approval process by the board, audit committee, independent directors, and supervisory board. The document also states that the transaction will be submitted to the shareholders' meeting for approval. There is no financial statement or report data, nor is this a transcript, earnings release, or capital update. The document is a formal announcement of a related-party transaction, which fits the category of Regulatory Filings (RNS) as it is a regulatory disclosure about a significant related-party transaction and not a financial report or other specific filing type.
2023-09-15 Chinese
百奥泰 第二届监事会第十次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a resolution passed at the 10th meeting of the 2nd Supervisory Board of 百奥泰生物制药股份有限公司. It details the meeting's convening, attendance, and the approval of a related-party transaction agreement. The document is short (1032 characters) and serves as a public disclosure of the supervisory board's decision rather than a full report or financial statement. It does not contain financial data, audit results, or detailed management discussion. It is not an annual or interim report, nor a call transcript or capital update. It is a regulatory announcement about a board meeting resolution, which fits best under Regulatory Filings (RNS).
2023-09-15 Chinese
百奥泰 关于召开2023年第一次临时股东大会的通知
Regulatory Filings Classification · 95% confidence The document is a detailed notice about the convening of the 2023 first extraordinary general meeting (临时股东大会) of 百奥泰生物制药股份有限公司. It includes information about the meeting date, voting methods, agenda items, shareholder eligibility, registration procedures, and proxy forms. There is no financial data, earnings information, or report content. The document is an announcement of a shareholder meeting rather than a report or results announcement. It does not contain voting results or legal proceedings updates. Therefore, it fits best as a Regulatory Filing (RNS) because it is a formal regulatory announcement about the meeting and voting procedures, not the meeting materials themselves or voting results.
2023-09-15 Chinese
百奥泰 独立董事关于第二届董事会第十一次会议相关事项的独立意见
Regulatory Filings
2023-09-15 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.